Related references
Note: Only part of the references are listed.Natural Products as Modulators of Nrf2 Signaling Pathway in Neuroprotection
Ignacio Moratilla-Rivera et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2023)
Multitarget Hybrid Fasudil Derivatives as a New Approach to the Potential Treatment of Amyotrophic Lateral Sclerosis
Olmo Martin-Camara et al.
JOURNAL OF MEDICINAL CHEMISTRY (2022)
CAPE and its synthetic derivative VP961 restore BACH1/NRF2 axis in Down Syndrome
Sara Pagnotta et al.
FREE RADICAL BIOLOGY AND MEDICINE (2022)
Boosting caffeic acid performance as antioxidant and monoamine oxidase B/catechol-O-methyltransferase inhibitor
Daniel Chavarria et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2022)
Extra Virgin Olive Oil Phenolic Extract on Human Hepatic HepG2 and Intestinal Caco-2 Cells: Assessment of the Antioxidant Activity and Intestinal Trans-Epithelial Transport
Martina Bartolomei et al.
ANTIOXIDANTS (2021)
Monoamine oxidases in age-associated diseases: New perspectives for old enzymes
Yohan Santin et al.
AGEING RESEARCH REVIEWS (2021)
Pharmacokinetics and Bioavailability of Monomethyl Fumarate Following a Single Oral Dose of Bafiertam™ (Monomethyl Fumarate) or Tecfidera(R) (Dimethyl Fumarate)
Thomas W. Lategan et al.
CNS DRUGS (2021)
Neuroprotective and antioxidative effects of pioglitazone in brain tissue adjacent to the ischemic core are mediated by PI3K/Akt and Nrf2/ARE pathways
Yi Zhao et al.
JOURNAL OF MOLECULAR MEDICINE-JMM (2021)
Safety and efficacy of pioglitazone for the delay of cognitive impairment in people at risk of Alzheimer's disease (TOMMORROW): a prognostic biomarker study and a phase 3, randomised, double-blind, placebo-controlled trial
Daniel K. Burns et al.
LANCET NEUROLOGY (2021)
Reassessment of Pioglitazone for Alzheimer's Disease
Ann M. Saunders et al.
FRONTIERS IN NEUROSCIENCE (2021)
Lipophilic ferulic acid derivatives protect PC12 cells against oxidative damage via modulating beta-amyloid aggregation and activating Nrf2 enzymes
Yu Wu et al.
FOOD & FUNCTION (2020)
Newly developed reversible MAO-B inhibitor circumvents the shortcomings of irreversible inhibitors in Alzheimer's disease
Jong-Hyun Park et al.
SCIENCE ADVANCES (2019)
Lights and shadows of electrophile signaling: focus on the Nrf2-Keap1 pathway
Filippo Basagni et al.
FUTURE MEDICINAL CHEMISTRY (2019)
Benextramine and derivatives as novel human monoamine oxidases inhibitors: an integrated approach
Maria Luisa Di Paolo et al.
FEBS JOURNAL (2019)
Recent Advances of Natural Polyphenols Activators for Keap1-Nrf2 Signaling Pathway
Yanping Zhou et al.
CHEMISTRY & BIODIVERSITY (2019)
Merging memantine and ferulic acid to probe connections between NMDA receptors, oxidative stress and amyloid-β peptide in Alzheimer's disease
Michela Rosini et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2019)
Pioglitazone Attenuates Lipopolysaccharide-Induced Oxidative Stress, Dopaminergic Neuronal Loss and Neurobehavioral Impairment by Activating Nrf2/ARE/HO-1
Aya Zakaria et al.
NEUROCHEMICAL RESEARCH (2019)
Mechanistic enzymology in drug discovery: a fresh perspective
Geoffrey A. Holdgate et al.
NATURE REVIEWS DRUG DISCOVERY (2018)
The role of Nrf2 signaling in counteracting neurodegenerative diseases
Albena T. Dinkova-Kostova et al.
FEBS JOURNAL (2018)
Analysis of monoamine oxidase (MAO) enzymatic activity by high-performance liquid chromatography-diode array detection combined with an assay of oxidation with a peroxidase and its application to MAO inhibitors from foods and plants
Tomas Herraiz et al.
JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES (2018)
Redox Signaling by Reactive Electrophiles and Oxidants
Saba Parvez et al.
CHEMICAL REVIEWS (2018)
Neuroprotective Effect of Caffeic Acid Phenethyl Ester in A Mouse Model of Alzheimer's Disease Involves Nrf2/HO-1 Pathway
Fabiana Morroni et al.
AGING AND DISEASE (2018)
Hybrid caffeic acid derivatives as monoamine oxidases inhibitors: synthesis, radical scavenging activity, molecular docking studies and in silico ADMET analysis
Priyanka Dhiman et al.
CHEMISTRY CENTRAL JOURNAL (2018)
Pioglitazone for the treatment of Alzheimer's disease
Daniela Galimberti et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2017)
Evaluation of the Cellular and Animal Models for the Study of Antioxidant Activity: A Review
Huijuan Zhang et al.
JOURNAL OF FOOD SCIENCE (2017)
Monoamine oxidase B is elevated in Alzheimer disease neurons, is associated with γ-secretase and regulates neuronal amyloid β-peptide levels
Sophia Schedin-Weiss et al.
ALZHEIMERS RESEARCH & THERAPY (2017)
PPARs in the central nervous system: roles in neurodegeneration and neuroinflammation
Juan M. Zolezzi et al.
BIOLOGICAL REVIEWS (2017)
Targeting the Nrf2/Amyloid-Beta Liaison in Alzheimer's Disease: A Rational Approach
Elena Simoni et al.
ACS CHEMICAL NEUROSCIENCE (2017)
NINDS Exploratory Trials in Parkinson Disease (NET-PD) FS-ZONE Investigators. Pioglitazone in early Parkinson's disease: a phase 2, multicentre, double-blind, randomised trial. (vol 14, pg 795, 2015)
Chadwick W. Christine
LANCET NEUROLOGY (2015)
Dimethyl fumarate in the treatment of relapsing-remitting multiple sclerosis: an overview
Roberto Bomprezzi
THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS (2015)
Pioglitazone in early Parkinson's disease: a phase 2, multicentre, double-blind, randomised trial
Tanya Simuni et al.
LANCET NEUROLOGY (2015)
Synthesis and structure-activity relationship study of substituted caffeate esters as antinociceptive agents modulating the TREK-1 channel
Nuno Rodrigues et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2014)
Inhibition of monoamine oxidase (MAO) by β-carbolines and their interactions in live neuronal (PC12) and liver (HuH-7 and MH1C1) cells
Michael F. Santillo et al.
TOXICOLOGY IN VITRO (2014)
Caffeic acid phenethyl ester activation of Nrf2 pathway is enhanced under oxidative state: Structural analysis and potential as a pathologically targeted therapeutic agent in treatment of colonic inflammation
Hyunjeong Kim et al.
FREE RADICAL BIOLOGY AND MEDICINE (2013)
Design and synthesis of novel pyranone-based insulin sensitizers exhibiting in vivo hepatoprotective activity
Atul Goel et al.
MEDCHEMCOMM (2013)
Peroxisome Proliferator-Activated Receptor Gamma (PPAR-γ) and Neurodegenerative Disorders
Yu-Chang Chen et al.
MOLECULAR NEUROBIOLOGY (2012)
Molecular Insights into Human Monoamine Oxidase B Inhibition by the Glitazone Antidiabetes Drugs
Claudia Binda et al.
ACS MEDICINAL CHEMISTRY LETTERS (2012)
The PPAR-γ agonist pioglitazone modulates inflammation and induces neuroprotection in parkinsonian monkeys
Christine R. Swanson et al.
JOURNAL OF NEUROINFLAMMATION (2011)
Modulation of Nrf2/ARE Pathway by Food Polyphenols: A Nutritional Neuroprotective Strategy for Cognitive and Neurodegenerative Disorders
Giovanni Scapagnini et al.
MOLECULAR NEUROBIOLOGY (2011)
Double antioxidant activities of rosiglitazone against high glucose-induced oxidative stress in hepatocyte
Xin Wang et al.
TOXICOLOGY IN VITRO (2011)
Identification of novel monoamine oxidase B inhibitors by structure-based virtual screening
Werner J. Geldenhuys et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2010)
Hydroxycinnamates and their in vitro and in vivo antioxidant activities
Fereidoon Shahidi et al.
PHYTOCHEMISTRY REVIEWS (2010)
The PPARγ agonist pioglitazone is effective in the MPTP mouse model of Parkinson's disease through inhibition of monoamine oxidase B
L. P. Quinn et al.
BRITISH JOURNAL OF PHARMACOLOGY (2008)
Investigation of racemisation of the enantiomers of glitazone drug compounds at different pH using chiral HPLC and chiral CE
Babak Jamali et al.
JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS (2008)
Isolation and structure elucidation of the new fungal metabolite (-)-xylariamide A
RA Davis
JOURNAL OF NATURAL PRODUCTS (2005)
Protective action of the peroxisome proliferator-activated receptor-γ agonist pioglitazone in a mouse model of Parkinson's disease
T Breidert et al.
JOURNAL OF NEUROCHEMISTRY (2002)
Caffeic acid phenethyl ester and curcumin: A novel class of heme oxygenase-1 inducers
G Scapagnini et al.
MOLECULAR PHARMACOLOGY (2002)
Share Paper
